[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"primary-light-chain-amyloidosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:primary-light-chain-amyloidosis":39},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100595986",false,"NCT07039578","Study Evaluating the Efficacy and Safety of CM336 Injection in the Treatment of Light-Chain Amyloidosis","An Open-Label, Multi-Center, Phase II Clinical Study Evaluating the Efficacy and Safety of CM336 Injection in the Treatment of Relapsed or Refractory Primary Light-Chain Amyloidosis","Inclusion Criteria:\n\n* Voluntary provision of written informed consent and ability to comply with protocol requirements.\n* Age ≥18 years, any gender.\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2.\n* Confirmed diagnosis of primary light-chain (AL) amyloidosis.\n* Relapsed or refractory primary AL amyloidosis.\n* Measurable hematologic disease at screening (per protocol-defined criteria).\n* Involvement of ≥1 amyloid-affected organ.\n* Adequate organ function meeting all protocol-specified criteria within 3 days prior to first dose.\n\nExclusion Criteria:\n\n* Current or prior diagnosis of multiple myeloma.\n* Received anti-AL amyloidosis therapy within protocol-specified timeframe prior to first dose.\n* Clinically significant cardiovascular or cerebrovascular disease.\n* Any active or uncontrolled infection meeting protocol-defined criteria.\n* Any other condition deemed by the Investigator to preclude safe study participation.","ALL","18 Years",{"count":18,"type":19},90,"ESTIMATED","INTERVENTIONAL",[22],"PHASE2","to Evaluate the Efficacy and Safety of CM336 (BCMA\u002FCD3 Bispecific Antibody) in Adults with Relapsed or Refractory Primary Light-Chain Amyloidosis",[25],"Primary Light-Chain Amyloidosis","RECRUITING","2025-11-20",{"date":29,"type":30},"2025-11-26","ACTUAL",{"date":32,"type":30},"2025-07-25",{"date":34,"type":19},"2029-07-31",{"name":36,"class":37},"Keymed Biosciences Co.Ltd","INDUSTRY",2,""]